RADX Stock Risk & Deep Value Analysis
Radiopharm Theranostics Ltd
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on RADX
We analyzed Radiopharm Theranostics Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RADX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
RADX Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Radiopharm Theranostics Ltd (RADX)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$85.69M
RADX Deep Value Analysis
RADX Red Flags & Warning Signs
- ⚠
Negative or inconclusive clinical trial results for lead candidates
- ⚠
Higher-than-expected cash burn leading to further significant dilution
- ⚠
Delays in clinical trials or regulatory processes
- ⚠
Competitor advancements or market entry of superior therapies
Unlock RADX Red Flags & Risk Warnings
Create a free account to see the full analysis
RADX Financial Health Metrics
Market Cap
$85.69M
RADX Competitive Moat Analysis
Sign in to unlockMoat Rating
None
Moat Trend
Expanding
Moat Sources
1 Identified
The potential moat relies entirely on the successful progression of its clinical pipeline, leading to regulatory approval and robust patent protection. Until clinical success is achieved and market exclusivity secured, the moat is not durable. It is currently expanding through ongoing R&D and clinical data generation.
RADX Competitive Moat Analysis
Sign up to see competitive advantages
RADX Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Financial Results (Estimated late Feb/early Mar 2026)
- •Interim Phase 2 clinical data readout for lead candidate(s) (e.g., PTPµ, PSMA, Granzyme B programs) (Expected Q2-Q3 2026)
- •Presentations at major oncology conferences (e.g., ASCO, SNMMI) (May-June 2026)
Medium-Term (6-18 months)
- •Expansion of clinical programs into additional indications or new territories (6-18 months)
- •Potential strategic partnership or licensing agreement with a larger pharmaceutical company (6-18 months)
- •Initiation of additional Phase 2 or Phase 3 trials for promising candidates (12-18 months)
Long-Term (18+ months)
- •Major clinical trial success leading to regulatory approval filings (18+ months)
- •Establishment as a key player in targeted radiopharmaceutical theranostics (3-5 years)
- •Acquisition by a larger pharmaceutical company seeking to enter/expand in the theranostics space (3-5 years)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
RADX Bull Case: What Could Go Right
- ✓
Positive Phase 2 clinical trial data readouts for any lead candidate
- ✓
Announcement of new strategic partnerships or significant non-dilutive funding
- ✓
Progress in IND filings or expansion into new clinical programs
- ✓
Signs of strong institutional investor interest or capital raises from reputable funds
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
